ArticleAging and disease2021
Identifying Biomarkers Associated with Venous Infarction in Acute/Subacute Cerebral Venous Thrombosis.
Article in Aging and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Inflammatory biomarkers in cerebral venous thrombosis versus ischemic stroke: a network meta-analysis.Frontiers in neurology · 2025Pooled it
- Glucocorticoids combined with anticoagulation modulate the central NLRP3/NETosis inflammatory process in patients with severe cerebral venous thrombosis: a human mechanistic exploratory study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Predicting 3-month prognosis of cerebral venous thrombosis: a machine learning approach incorporating inflammatory markers.Frontiers in neurology · 2026Article
- Inflammatory markers and clinical outcomes in acute/subacute severe cerebral venous thrombosis: the role of glucocorticoid therapy.BMC neurology · 2025Article
- An Unusual Case of Cerebral Venous Sinus Thrombosis With Negative D-dimer Mimicking Giant Cell Arteritis.Cureus · 2025Article
- Claudin proteins and hemorrhage severity in aneurysmal subarachnoid hemorrhage: Correlation with modified Fisher score but not functional outcome.Neurosurgical review · 2025Article
- Predictive Value of Combined CRP and INR for Intracranial Hypertension in Cerebral Venous Thrombosis.Immunity, inflammation and disease · 2025Article
- Steroid therapy for severe cerebral venous thrombosis with rare manifestations of parkinsonism: a case report and literature review.Acta neurologica Belgica · 2025Article
- Steroids combined with anticoagulant in acute/subacute severe cerebral venous thrombosis.Chinese medical journal · 2025Observational
- Diagnostic Value of Inflammatory Biomarkers in Intracranial Venous Thrombosis: A Multi-model Predictive Analysis.Cureus · 2024Article
- Steroids' Neuroprotective Potential in Severe Cerebral Venous Thrombosis: Experimental and Clinical Exploration of NLRP3 Inflammasome Inhibition.CNS neuroscience & therapeutics · 2024Article
- Maggot Kinase and Natural Thrombolytic Proteins.ACS omega · 2024Review
- Expression and metabolism profiles of CVT associated with inflammatory responses and oxygen carrier ability in the brain.CNS neuroscience & therapeutics · 2024Article
- Diagnostic efficacy of ACA, aβ2-GP1, hs-CRP, and Hcy for cerebral infarction and their relationship with the disease severity.American journal of translational research · 2024Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Intracranial hypertension after cerebral venous thrombosis-Risk factors and outcomes.CNS neuroscience & therapeutics · 2023Article
- C-reactive protein and D-dimer in cerebral vein thrombosis: Relation to clinical and imaging characteristics as well as outcomes in a French cohort study.Research and practice in thrombosis and haemostasis · 2023Article
- An Exploration of Anti-Inflammatory Therapy in Acute/Subacute Severe Cerebral Venous Thrombosis with Hereditary Protein C/S Deficiency: Case Series.Journal of inflammation research · 2023Article
- A novel severe cerebral venous thrombosis rat model based on semi-ligation combined with ferric chloride and thrombin.CNS neuroscience & therapeutics · 2022Article
- Activating cGAS-STING axis contributes to neuroinflammation in CVST mouse model and induces inflammasome activation and microglia pyroptosis.Journal of neuroinflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among cerebral venous thrombosis (CVT) patients, those with venous infarction have more severe clinical presentations and worse outcomes. Identifying biomarkers associated with venous infarction in CVT may help understand the pathogenesis and provide potentially useful therapeutic markers. Fifty-two CVT patients were prospectively recruited and divided into three groups: acute/subacute CVT with venous infarction (ASVI, n=30), without venous infarction (ASOVI, n=13), and chronic CVT (n=9). Blood brain barrier (BBB) permeability-related proteins, including claudin-5, occludin, matrix metalloproteinase-9, glial fibrillary acidic protein, and S100B, and inflammation-related factor high-sensitivity C-reactive protein (hs-CRP), were tested in serum and/or cerebrospinal fluid upon admission. We compared these biomarkers between the three groups and investigated their associations with venous infarction and clinical symptom severity in acute/subacute CVT patients on admission using the NIH Stroke Scale (NIHSS). Serum hs-CRP was significantly higher in acute/subacute CVT patients than chronic CVT patients. For acute/subacute CVT patients, levels were significantly higher in the ASVI group than the ASOVI group for serum claudin-5 (medians 2.80 vs. 2.50 mg/I, respectively, P = 0.039) and hs-CRP (medians 17.25 vs. 2.27 mg/l, respectively, P = 0.003). Both these biomarkers, analyzed as categorical or continuous variables, were also significantly associated with venous infarction in acute/subacute CVT patients after logistic regression analysis. Additionally, hs-CRP was positively correlated with the NIHSS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.